Today, continuous glucose monitoring (CGM) is a standard diagnostic option for patients with diabetes, at least for those with type 1 diabetes and those with type 2 diabetes on insulin therapy, according to international guidelines. The switch from spot capillary blood glucose measurement to CGM was driven by the extensive and immediate support and facilitation of diabetes management CGM offers. In patients not using insulin, the benefits of CGM are not so well studied/obvious. In such patients, factors like well-being and biofeedback are driving CGM uptake and outcome. Apps can combine CGM data with data about physical activity and meal consumption for therapy adjustments. Personalized data management and coaching is also more feasible with CGM data. The same holds true for digitalization and telemedicine intervention ("virtual diabetes clinic"). Combining CGM data with Smart Pens ("patient decision support") helps to avoid missing insulin boluses or insulin miscalculation. Continuous glucose monitoring is a major pillar of all automated insulin delivery systems, which helps substantially to avoid acute complications and achieve more time in the glycemic target range. These options were discussed by a group of German experts to identify concrete gaps in the care structure, with a view to the necessary structural adjustments of the health care system., Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: ATh is an independent consultant and expert in CGM systems and diabetes technology; he receives gratuities and lecture fees from EvivaMed, Dexcom, IfDT Ulm, Berlin-Chemie, Novo-Nordisk, and Sanofi. TH receives fees for lectures and consultancy from Lilly, Novo-Nordisk, Sanofi, Abbott, Dexcom, MSD, Boehringer Ingelheim, and Ascensia. ATo makes presentations and takes part in the advisory boards of Astra, Bayer, Dexcom, and Lilly. BK receives fees for participation in the advisory boards of Berlin-Chemie, embecta, Insulet, Bayer, Sanofi, and Dexcom and lecture fees from Berlin-Chemie, Insulet, Dexcom, Novo-Nordisk, Sanofi, Roche Diabetes, and Hello Better. OK receives lecture/consultancy fees from Amgen, Daiichi Sankyo, Dexcom, Diamyd Medical, and Sanofi and is a stakeholder in DreaMed Inc. DE receives fees from Berlin-Chemie and Dexcom. He took part in the advisory boards of Dexcom, Roche Diabetes Care, and mySugr. JK receives fees for participation in the advisory boards of Novo-Nordisk, Lilly, BD, Abbott, Astra Zeneca, MSD, and Dexcom and lecture fees from Novo-Nordisk, Sanofi, Lilly, Berlin-Chemie, Bayer, Glaxo, MSD, Astra Zeneca, Boehringer-Ingelheim, Roche Diabetes, Abbott, Dexcom, Medtronic, and VitalAire. OS-O receives fees for lectures or participation in consultation committees of Abbott Diabetes Care, Roche Diabetes, Ypsomed, Dexcom, VitalAire, Ascensia, Medtronic, Eli Lilly, Boehringer Ingelheim, Novo-Nordisk, Berlin Chemie, Sanofi, MSD, AstraZeneca, and Chiesi. RK receives consulting fees from Dexcom and Medtronic, lecture fees, and consultation fees from Abbott. TS states having received lecture fees and participation in the advisory boards of Abbott, Dexcom, Medtronic, Roche, Ascensia, Berlin Chemie, Lilly, Novo-Nordisk, and Sanofi. NH received speaker fees from Novo-Nordisk, Ascensia, Sanofi, Roche, Lilly, Dexcom, and Abbott and participated in the advisory boards of the companies Abbott and BD. LH is a consultant for Abbott, embecta, Lifecare (also member of the Board of Directors), Medtronic EU Advisory Board, Dexcom Germany, Roche Diagnostics Diabetes Care Germany, Unomedical, Spiden, and Perfood. He is part owner of the Profil Institut für Stoffwechselforschung in Neuss, Germany, Science Consulting in Diabetes GmbH, Düsseldorf, Germany, and diateam GmbH, Bad Mergentheim, Germany.